Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
IRMD Iradimed Corp
- Stocks
- Healthcare
- NASDAQ: IRMD
Price (delayed)
$53.23
Market cap
$676.83M
P/E Ratio
33.9
Dividend/share
$0.62
EPS
$1.57
Enterprise value
$626.55M
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging ('MRI') compatible medical devices. It's the only known provider of a non-magnetic intravenous ('IV') infusion pump system
Highlights
The company's debt has shrunk by 97% YoY and by 62% QoQ
IRMD's price to earnings (P/E) is 47% lower than its 5-year quarterly average of 64.2
Iradimed's quick ratio has decreased by 2.6% YoY
Key stats
What are the main financial stats of IRMD
Market
Valuations
Earnings
Shares outstanding
12.72M
Market cap
$676.83M
Enterprise value
$626.55M
Price to earnings (P/E)
33.9
Price to book (P/B)
7.52
Price to sales (P/S)
9.01
EV/EBIT
25.08
EV/EBITDA
24.32
EV/Sales
8.34
Revenue
$75.15M
Gross profit
$57.8M
Operating income
$22.65M
Net income
$19.78M
EBIT
$24.98M
EBITDA
$25.76M
Free cash flow
$13.78M
Per share
Balance sheet
Liquidity
EPS
$1.57
EPS diluted
$1.55
Free cash flow per share
$1.08
Book value per share
$7.08
Revenue per share
$5.91
TBVPS
$7.74
Total assets
$101.73M
Total liabilities
$11.68M
Debt
$59,221
Equity
$90.05M
Working capital
$66.66M
Debt to equity
0
Current ratio
8.87
Quick ratio
7.44
Net debt/EBITDA
-1.95
Margins
Efficiency
Dividend
EBITDA margin
34.3%
Gross margin
76.9%
Net margin
26.3%
Operating margin
30.1%
Return on assets
20.6%
Return on equity
23.3%
Return on invested capital
72.5%
Return on capital employed
26.8%
Return on sales
33.2%
Dividend yield
1.16%
DPS
$0.62
Payout ratio
39.5%
IRMD stock price
How has the Iradimed stock price performed over time
Intraday
1.26%
1 week
4.33%
1 month
1.8%
1 year
25.39%
YTD
-3.22%
QTD
1.43%
Financial performance
How have Iradimed's revenue and profit performed over time
Revenue
$75.15M
Gross profit
$57.8M
Operating income
$22.65M
Net income
$19.78M
Gross margin
76.9%
Net margin
26.3%
The gross profit is up by 12% YoY and by 2.6% QoQ
The company's revenue rose by 11% YoY and by 2.6% QoQ
Iradimed's net income has increased by 10% YoY and by 2.9% from the previous quarter
The company's operating income rose by 9% YoY and by 3.1% QoQ
Price vs fundamentals
How does IRMD's price correlate with its fundamentals
Growth
What is Iradimed's growth rate over time
Valuation
What is Iradimed stock price valuation
P/E
33.9
P/B
7.52
P/S
9.01
EV/EBIT
25.08
EV/EBITDA
24.32
EV/Sales
8.34
IRMD's price to earnings (P/E) is 47% lower than its 5-year quarterly average of 64.2
Iradimed's EPS has increased by 11% YoY and by 3.3% QoQ
Iradimed's equity has increased by 18% YoY and by 3.7% QoQ
The price to book (P/B) is 12% higher than the 5-year quarterly average of 6.7
The company's revenue rose by 11% YoY and by 2.6% QoQ
The price to sales (P/S) is 2.4% higher than the last 4 quarters average of 8.8 but 2.1% lower than the 5-year quarterly average of 9.2
Efficiency
How efficient is Iradimed business performance
Iradimed's return on equity has decreased by 5% YoY
Iradimed's return on invested capital has decreased by 3.5% YoY
Dividends
What is IRMD's dividend history
DPS
$0.62
Dividend yield
1.16%
Payout ratio
39.5%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Iradimed financials performed over time
Iradimed's total assets has increased by 16% YoY and by 3.5% from the previous quarter
The current ratio has declined by 6% year-on-year
The company's debt is 100% lower than its equity
The debt to equity has plunged by 100% YoY
The company's debt has shrunk by 97% YoY and by 62% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.